May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and ...
Renal Denervation
This channel includes news and new technology innovations for renal denervation used to treat hypertension. Renal denervation is a catheter-based therapy. The catheter is into the renal artery and delivers radio-frequency energy to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys. This enables greater filtration of the blood and removal of excess water that causes hypertension.
May 30, 2018
May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now ...
May 30, 2018
May 23, 2018 – At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-ON ...
May 23, 2018
April 16, 2018 — Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational ...
April 16, 2018
August 31, 2017 — Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial ...
August 31, 2017October 11, 2016 — Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral ...
October 11, 2016
August 23, 2016 — Technavio analysts forecast the global renal denervation market to grow at a compound annual growth ...
August 23, 2016
February 17, 2016 — Up to 10 percent of people with high blood pressure have resistant hypertension — high blood ...
February 17, 2016
Robert Schwartz, M.D., medical director at the Minnesota Heart Institute, explains new applications for denervation ...
November 03, 2015
May 5, 2015 — Medtronic plc announced the start of a clinical study to determine whether paroxysmal and persistent atria ...
May 05, 2015
May 4, 2015 — Boston Scientific Corp. is taking a new approach to evaluate the performance of the Vessix Renal ...
May 04, 2015April 1, 2015 — Medtronic plc announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a phased ...
April 01, 2015
February 12, 2015 — Ablative Solutions Inc. announced the addition of Michael Weber, M.D., FACP, FACC, FAHA, to its ...
February 12, 2015November 17, 2014 — VIVA Physicians, a not-for-profit organization in the field of vascular medicine and intervention ...
November 17, 2014
October 8, 2014 — St. Jude Medical Inc. announced 12-month outcome data from the EnligHTN III study, which demonstrated ...
October 08, 2014© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now